Estimating cost-offsets of new medications: Use of new antipsychotics and mental health costs for schizophrenia

Estimation of the effect of one treatment compared to another in the absence of randomization is a common problem in biostatistics. An increasingly popular approach involves instrumental variables—variables that are predictive of who received a treatment yet not directly predictive of the outcome. When treatment is binary, many estimators have been proposed: method-of-moments estimators using a two-stage least-squares procedure, generalized-method-of-moments estimators using two-stage predictor substitution or two-stage residual inclusion procedures, and likelihood-based latent variable approaches. The critical assumptions to the consistency of two-stage procedures and of the likelihood-based procedures differ. Because neither set of assumptions can be completely tested from the observed data alone, comparing the results from the different approaches is an important sensitivity analysis. We provide a general statistical framework for estimation of the casual effect of a binary treatment on a continuous outcome using simultaneous equations to specify models. A comparison of health care costs for adults with schizophrenia treated with newer atypical antipsychotics and those treated with conventional antipsychotic medications illustrates our methods. Surprisingly large differences in the results among the methods are investigated using a simulation study. Several new findings concerning the performance in terms of precision and robustness of each approach in different situations are obtained. We illustrate that in general supplemental information is needed to determine which analysis, if any, is trustworthy and reaffirm that comparing results from different approaches is a valuable sensitivity analysis. Copyright © 2011 John Wiley & Sons, Ltd.

[1]  T. Andersen THE ECONOMETRICS OF FINANCIAL MARKETS , 1998, Econometric Theory.

[2]  J. Lieberman,et al.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. , 2006, The American journal of psychiatry.

[3]  A. Wald The Fitting of Straight Lines if Both Variables are Subject to Error , 1940 .

[4]  J. Hausman Specification tests in econometrics , 1978 .

[5]  N. Best,et al.  Convergence Diagnosis and Output Analysis Software for Gibbs sampling output Version 0.30 , 1995 .

[6]  J. Copas,et al.  Inference for Non‐random Samples , 1997 .

[7]  Jeffrey M. Woodbridge Econometric Analysis of Cross Section and Panel Data , 2002 .

[8]  N. Duan Smearing Estimate: A Nonparametric Retransformation Method , 1983 .

[9]  Paul J Rathouz,et al.  Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. , 2008, Journal of health economics.

[10]  J. Robins Data, Design, and Background Knowledge in Etiologic Inference , 2001, Epidemiology.

[11]  P. Schmidt,et al.  Limited-Dependent and Qualitative Variables in Econometrics. , 1984 .

[12]  G. Melnick,et al.  The Effect of Medicare Health Maintenance Organizations on Hospitalization Rates for Ambulatory Care-Sensitive Conditions , 2006, Medical care.

[13]  James J. Heckman,et al.  Identification of Causal Effects Using Instrumental Variables: Comment , 1996 .

[14]  J. Rassen,et al.  Confounding Control in Healthcare Database Research: Challenges and Potential Approaches , 2010, Medical care.

[15]  D. McCaffrey,et al.  Effect of Insurance on Mortality in an HIV-Positive Population in Care , 2001 .

[16]  S. Normand,et al.  Correlated bivariate continuous and binary outcomes: Issues and applications , 2009, Statistics in medicine.

[17]  J. Angrist,et al.  Identification and Estimation of Local Average Treatment Effects , 1995 .

[18]  J. Heckman Dummy Endogenous Variables in a Simultaneous Equation System , 1977 .

[19]  J. Stock,et al.  Instrumental Variables Regression with Weak Instruments , 1994 .

[20]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[21]  Jay Bhattacharya,et al.  Estimating probit models with self‐selected treatments , 2006, Statistics in medicine.

[22]  Dylan S. Small,et al.  Extended Instrumental Variables Estimation for Overall Effects , 2008, The international journal of biostatistics.

[23]  Joshua D. Angrist,et al.  Mostly Harmless Econometrics: An Empiricist's Companion , 2008 .

[24]  F. Lichtenberg,et al.  Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. , 2001, Health affairs.

[25]  H. Sox,et al.  Five next steps for a new national program for comparative-effectiveness research. , 2010, The New England journal of medicine.

[26]  J. Robins,et al.  Analysis of semi-parametric regression models with non-ignorable non-response. , 1997, Statistics in medicine.

[27]  Joshua D. Angrist,et al.  Identification of Causal Effects Using Instrumental Variables , 1993 .

[28]  Dylan S. Small,et al.  Sensitivity Analysis for Instrumental Variables Regression With Overidentifying Restrictions , 2007 .

[29]  E. Vytlacil Independence, Monotonicity, and Latent Index Models: An Equivalence Result , 2002 .

[30]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.